BioNTech Investor Day Presentation Deck

2 Variant-adapted vaccines | Omicron-containing modified variant vaccines as 4th dose elicit improved Omicron neutralization response FFRNT 50 10,000 1,000 100 10 Participants WITHOUT evidence of infection up to 1 month after first study vaccination >55 years old participants, 30 and 60 µg dose 501.1 78.4 OMI 30 µg n=17 FFRNT, fluorescent foci reduction neutralization test; LOD, limit of detection. Internal data. BA.1 822.0 145.3 OMI 60 µg n=18 771.3 226.3 Bivalent 30 μµg n=13 BA.4/BA.5 response lower than that of BA.1 BA.4/5 678.1 137.2 Bivalent 60 µg n=18 2 LATNI [DAN Pandemic prep. LOD CAR Pfizer BIONTECH 77

View entire presentation